Weight-Loss Drug Halves Knee Pain in Two Trials
Weight-Loss Drug Halves Knee Pain in Two Trials
Weight-Loss Drug Halves Knee Pain in Two Trials
Key points
اہم نکات
मुख्य बातें
- An experimental weight-loss drug eased painful knee osteoarthritis in two large clinical trials, Medical Xpress reports.
- In the Northwestern University-led Phase III trials of more than 1,000 people, those on the highest dose of retatrutide lost about a quarter of their body weight, and about two-thirds saw their knee pain fall by at least half, compared with 38 percent on placebo.
- The findings were published in the New England Journal of Medicine, and maker Eli Lilly plans to seek US approval for weight loss in early 2027.
- An experimental weight-loss drug eased painful knee osteoarthritis in two large clinical trials, Medical Xpress reports.
- In the Northwestern University-led Phase III trials of more than 1,000 people, those on the highest dose of retatrutide lost about a quarter of their body weight, and about two-thirds saw their knee pain fall by at least half, compared with 38 percent on placebo.
- The findings were published in the New England Journal of Medicine, and maker Eli Lilly plans to seek US approval for weight loss in early 2027.
- An experimental weight-loss drug eased painful knee osteoarthritis in two large clinical trials, Medical Xpress reports.
- In the Northwestern University-led Phase III trials of more than 1,000 people, those on the highest dose of retatrutide lost about a quarter of their body weight, and about two-thirds saw their knee pain fall by at least half, compared with 38 percent on placebo.
- The findings were published in the New England Journal of Medicine, and maker Eli Lilly plans to seek US approval for weight loss in early 2027.
An experimental weight-loss drug eased painful knee osteoarthritis in two large clinical trials, Medical Xpress reports. In the Northwestern University-led Phase III trials of more than 1,000 people, those on the highest dose of retatrutide lost about a quarter of their body weight, and about two-thirds saw their knee pain fall by at least half, compared with 38 percent on placebo. The findings were published in the New England Journal of Medicine, and maker Eli Lilly plans to seek US approval for weight loss in early 2027.
An experimental weight-loss drug eased painful knee osteoarthritis in two large clinical trials, Medical Xpress reports. In the Northwestern University-led Phase III trials of more than 1,000 people, those on the highest dose of retatrutide lost about a quarter of their body weight, and about two-thirds saw their knee pain fall by at least half, compared with 38 percent on placebo. The findings were published in the New England Journal of Medicine, and maker Eli Lilly plans to seek US approval for weight loss in early 2027.
An experimental weight-loss drug eased painful knee osteoarthritis in two large clinical trials, Medical Xpress reports. In the Northwestern University-led Phase III trials of more than 1,000 people, those on the highest dose of retatrutide lost about a quarter of their body weight, and about two-thirds saw their knee pain fall by at least half, compared with 38 percent on placebo. The findings were published in the New England Journal of Medicine, and maker Eli Lilly plans to seek US approval for weight loss in early 2027.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।